FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W45985156> ?p ?o ?g. }

• W45985156 endingPage "281" @default.
• W45985156 startingPage "269" @default.
• W45985156 abstract "To review the electrophysiologic properties and the in vitro, ex vivo, animal, and human data regarding proarrhythmic effects of intravenous vasopressors.A comprehensive (MEDLINE) search (1960-1994) was conducted for dopamine, epinephrine, norepinephrine, phenylephrine, and methoxamine.In vitro and ex vivo studies and investigations performed in animals or humans reporting electrophysiologic and/or proarrhythmic effects of the above intravenous vasopressors were selected. A comprehensive search of all human studies involving these agents was conducted to reveal any proarrhythmic effects that may have been reported. In addition, case reports of proarrhythmic effects associated with these agents were reviewed.Data regarding electrophysiologic and proarrhythmic effects of these agents were extracted from in vitro, ex vivo, animal, and human studies. Because few studies with the specific purpose of investigating proarrhythmic effects of vasopressors have been performed in humans, all studies involving these drugs for evaluation of hemodynamic effects, clinical efficacy, or other endpoints in humans were reviewed. In addition, data were extracted from case reports of proarrhythmic effects associated with these agents.Dopamine increases automaticity in Purkinje fibers and has a biphasic effect on action-potential duration. Dopamine has caused both atrial and ventricular tachyarrhythmias in animals. Human data have revealed dose-related sinus tachycardia, with few reports of clinically significant ventricular arrhythmias. Epinephrine shortens sinus cycle length, increases atrial and ventricular automaticity, promotes atrioventricular nodal conduction, and decreases ventricular effective refractory period (ERP). It is well known to induce ventricular fibrillation and decrease the ventricular fibrillation threshold (VFT) in ex vivo models as well as intact animals. In humans, epinephrine may cause dose-related sinus tachycardia, supraventricular arrhythmias, or, more commonly, ventricular arrhythmias. Norepinephrine increases automaticity of the sinoatrial node, atria, and ventricles; promotes atrioventricular nodal conduction; and decreases ventricular ERP. In vitro/ex vivo and animal data have shown that norepinephrine significantly decreases VFT. Although electrophysiologic studies suggest that norepinephrine may be proarrhythmic, few supporting data exist in humans. Phenylephrine demonstrates differential electrophysiologic effects in atrial and ventricular tissue. Most data suggest that phenylephrine causes prolongation of the ventricular ERP. Rather than being proarrhythmic, phenylephrine may be protective against arrhythmias. The drug elevates VFT in dogs. In humans, phenylephrine effectively terminates supraventricular tachycardias and may be protective against ventricular arrhythmias. Like phenylephrine, methoxamine elevates the repetitive extrasystolic, atrial, and ventricular fibrillatory thresholds. Methoxamine also may have antiarrhythmic effects because of alpha-receptor stimulation and reflex vagal activity. Despite the relatively low risk of arrhythmogenicity associated with intravenous vasopressors, patients should be monitored for potential proarrhythmic effects and appropriate action taken as necessary. Critically ill patients often have concurrent conditions, electrolyte disturbances, and underlying arrhythmias that predispose them to a higher risk of vasopressor proarrhythmic effects.Controlled data supporting the proarrhythmic potential of intravenous vasopressors in humans are lacking. Sinus tachycardia, asymptomatic ventricular ectopic activity, and other ventricular or supraventricular arrhythmias have been reported in association with dopamine and epinephrine. Phenylephrine and methoxamine have been associated with sinus bradycardia, but otherwise may be antiarrhythmic. Intravenous vasopressors appear relatively safe w" @default.
• W45985156 created "2016-06-24" @default.
• W45985156 creator A5012062477 @default.
• W45985156 creator A5012193533 @default.
• W45985156 creator A5024748503 @default.
• W45985156 creator A5037520504 @default.
• W45985156 creator A5072538819 @default.
• W45985156 date "1995-03-01" @default.
• W45985156 modified "2023-09-29" @default.
• W45985156 title "Proarrhythmic Effects of Intravenous Vasopressors" @default.
• W45985156 cites W1550288426 @default.
• W45985156 cites W1593607587 @default.
• W45985156 cites W1963645925 @default.
• W45985156 cites W1971217186 @default.
• W45985156 cites W1974180074 @default.
• W45985156 cites W1975551184 @default.
• W45985156 cites W1977161944 @default.
• W45985156 cites W1979217886 @default.
• W45985156 cites W1979697408 @default.
• W45985156 cites W1980491303 @default.
• W45985156 cites W1981369009 @default.
• W45985156 cites W1983245871 @default.
• W45985156 cites W1986459950 @default.
• W45985156 cites W1987847093 @default.
• W45985156 cites W1990763590 @default.
• W45985156 cites W1991096956 @default.
• W45985156 cites W1991638901 @default.
• W45985156 cites W1991676911 @default.
• W45985156 cites W1992310491 @default.
• W45985156 cites W1992442197 @default.
• W45985156 cites W1995646175 @default.
• W45985156 cites W1995768634 @default.
• W45985156 cites W1996479424 @default.
• W45985156 cites W1997202002 @default.
• W45985156 cites W2001464605 @default.
• W45985156 cites W2003373752 @default.
• W45985156 cites W2004768213 @default.
• W45985156 cites W2007627749 @default.
• W45985156 cites W2008402710 @default.
• W45985156 cites W2011205516 @default.
• W45985156 cites W2011436598 @default.
• W45985156 cites W2011476712 @default.
• W45985156 cites W2013519810 @default.
• W45985156 cites W2013594103 @default.
• W45985156 cites W2018048696 @default.
• W45985156 cites W2020502189 @default.
• W45985156 cites W2020707837 @default.
• W45985156 cites W2021568293 @default.
• W45985156 cites W2023855395 @default.
• W45985156 cites W2024972051 @default.
• W45985156 cites W2025329746 @default.
• W45985156 cites W2026069628 @default.
• W45985156 cites W2026182236 @default.
• W45985156 cites W2028076755 @default.
• W45985156 cites W2028710981 @default.
• W45985156 cites W2029456141 @default.
• W45985156 cites W2029891070 @default.
• W45985156 cites W2030408592 @default.
• W45985156 cites W2030479391 @default.
• W45985156 cites W2031855345 @default.
• W45985156 cites W2033198739 @default.
• W45985156 cites W2033296625 @default.
• W45985156 cites W2036117350 @default.
• W45985156 cites W2037786416 @default.
• W45985156 cites W2038877513 @default.
• W45985156 cites W2039632279 @default.
• W45985156 cites W2042494620 @default.
• W45985156 cites W2043220557 @default.
• W45985156 cites W2043765530 @default.
• W45985156 cites W2044446201 @default.
• W45985156 cites W2044764297 @default.
• W45985156 cites W2046756811 @default.
• W45985156 cites W2047811193 @default.
• W45985156 cites W2048555011 @default.
• W45985156 cites W2048854955 @default.
• W45985156 cites W2048899978 @default.
• W45985156 cites W2050335104 @default.
• W45985156 cites W2056327744 @default.
• W45985156 cites W2059014716 @default.
• W45985156 cites W2059616919 @default.
• W45985156 cites W2060431176 @default.
• W45985156 cites W2061386415 @default.
• W45985156 cites W2064422889 @default.
• W45985156 cites W2065652372 @default.
• W45985156 cites W2066165691 @default.
• W45985156 cites W2066317231 @default.
• W45985156 cites W2066833794 @default.
• W45985156 cites W2068632432 @default.
• W45985156 cites W2069642958 @default.
• W45985156 cites W2073534926 @default.
• W45985156 cites W2076486635 @default.
• W45985156 cites W2076793145 @default.
• W45985156 cites W2077952456 @default.
• W45985156 cites W2082174905 @default.
• W45985156 cites W2083368319 @default.
• W45985156 cites W2084148065 @default.
• W45985156 cites W2085851308 @default.
• W45985156 cites W2090865827 @default.

• next